ARNA stock information

Sector:

Healthcare

Description:

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

Arena Pharmaceuticals, Inc. website

Current Price

$99.99

RSI

89.75

Market Capitalization:

5.8B

Beta:

0.548

Volume:

5,429,629

Analyst Target Price:

$ 97.85

Economiic Fair Price:

Report DateFebruary 23, 2022

QuarterQ4

Forward Dividend N/A

Forward Dividend Rate N/A

Dividend N/A

Dividend Rate N/A

Payout Ratio N/A

Cash

Debt

EPS-9.72

Profit MarginN/A

Revenue Per Share TTM0.001

Return On Equity TTM-0.592

YoY Revenue Growth (TTM)

11.49 %

YoY Pre Tax Income Growth (TTM)

-54.75 %

YoY Free Cash Flow (TTM)

-52.96 %

QoQ Revenue Growth

45.95 %

QoQ Pre Tax Income Growth

-27.38 %

QoQ Free Cash Flow Growth

-13.62 %

2021 Revenue

$ 54K

-83.07 %

2020 Revenue

$ 319K

-99.96 %

2019 Revenue

$ 806.4M

4387.65 %

2018 Revenue

$ 18M

-15.78 %

2017 Revenue

$ 21.3M

-82.79 %

2016 Revenue

$ 124M

2021 Free Cash Flow

$ -523M

-47.78 %

2020 Free Cash Flow

$ -353.9M

-162.76 %

2019 Free Cash Flow

$ 563.9M

524.27 %

2018 Free Cash Flow

$ -132.9M

-99.09 %

2017 Free Cash Flow

$ -66.8M

-5.81 %

2016 Free Cash Flow

$ -63.1M

2021 Pre Tax Income

$ -616.4M

-52.31 %

2020 Pre Tax Income

$ -404.7M

-179.69 %

2019 Pre Tax Income

$ 507.9M

465.82 %

2018 Pre Tax Income

$ -138.8M

-44.90 %

2017 Pre Tax Income

$ -95.8M

-319.26 %

2016 Pre Tax Income

$ -22.9M

Arena Pharmaceuticals, Inc.(ARNA)